Light-Activated gel shows promise for rare skin cancer
Disease control
Recruiting now
This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…
Phase: PHASE3 • Sponsor: Soligenix • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC